PROJECT SUMMARY
Changes in ion channel biophysics and function due to mutation or disease-associated remodeling are
frequently assessed in isolated cells; yet translation of these mechanistic changes for therapeutic target
development is difficult and often fails due to the inherent lack of tissue-scale regulation that is missing
in isolated cell experiments. Sodium channel gain-of-function is a critical example of this translational
challenge, with well-identified ion channel biophysical dysfunction (i.e., gating); yet an estimated 16-
64% of congenital sodium channel gain-of-function patients present without an electrocardiographic
phenotype.
Our prior work demonstrated a proof-of-concept that modulation of ion concentrations in extracellular
nanodomains can conceal or unmask this gain-of-function, and these dynamics are an inherently
tissue-scale phenomenon, as the sodium channel enriched nanodomains adjacent to gap junctions at
the intercalated disc. The current proposal seeks to demonstrate that this concept has significant
potential for therapeutic target development and pre-clinical predictive assessment. Preliminary data
demonstrate that extracellular sodium and potassium (through co-regulation by intercalated disc-
localized potassium channels) can modulate the presentation of sodium channel gain-of-function in a
manner that depends on intercalated disc structure. We propose computational simulations (novel
structurally detailed tissue models) and experiments (isolated myocytes, ex vivo hearts, and in vivo
genetically-modified mice and peptide treated guinea pigs) to test the hypothesis that sodium and
potassium concentrations can serve as critical biomarkers that are co-factors for risk of
electrophysiological dysfunction in the setting of sodium channel gain-of-function and concomitant
perinexus expansion. While ion concentrations are already established biomarkers in clinical care, our
proposal will test the hypothesis that so called ‘normal’ ranges may indeed be pathological in patients
with sodium channel gain-of-function. Indeed, the standard collection of these biomarkers is an asset
for future work that will seek to identify patients at greater risk for electrophysiological dysfunction.
Upon successful completion of these aims, we will produce new mechanistic understanding of the
manifestation of sodium channel gain-of-function, which will demonstrate a mechanistic equivalency
between detection and therapy.